Rheumatoid Arthritis and Autoimmune Disease
Research activity includes rheumatoid arthritis in adults receiving methotrexate, with attention to inflammatory joint disease and immune-mediated pathology. The programme also reflects interest in biosimilar development for established TNF inhibitor therapy.
- Etanercept biosimilar evaluation
- American College of Rheumatology response outcomes
- Immunogenicity and safety in autoimmune treatment
These studies place rheumatology and biologic therapy at the centre of the sponsor’s clinical research portfolio.
Melanoma and Immuno-Oncology
The sponsor is active in previously untreated advanced melanoma, including unresectable and metastatic disease. Its research focus extends to immune checkpoint inhibition and comparative assessment of PD-1 inhibitor biosimilars.
- Nivolumab biosimilar development
- Advanced melanoma treatment
- Oncology immunogenicity and efficacy
This area highlights involvement in solid tumour care and immunotherapy for skin cancer.
Non-Small Cell Lung Cancer
Clinical research also covers advanced/metastatic non-squamous non-small cell lung cancer, with emphasis on first-line therapy and checkpoint blockade in thoracic oncology. The sponsor’s work includes comparative interest in pembrolizumab biosimilar development.
- Non-squamous NSCLC
- Pembrolizumab biosimilar
- Metastatic lung cancer management
These studies position lung cancer immunotherapy as a key therapeutic domain.
Healthy Volunteer Pharmacology
Work in healthy male volunteers supports investigation of pharmacokinetics, safety, and immunogenicity for biosimilar biologics. This research area is linked to the sponsor’s broader focus on comparative biologic development.
- Pharmacokinetic profiling
- Safety assessment
- Immunogenicity evaluation
The portfolio includes early clinical assessment relevant to biologic medicines across multiple therapeutic classes.
